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Abstract
Genetic variants of Leucine-Rich Repeat Kinase 2 (LRRK2) are associated with a significantly enhanced risk for Parkinson
disease, the second most common human neurodegenerative disorder. Despite major efforts, our understanding of LRRK2
biological function and regulation remains rudimentary. In the present study we analyze LRRK2 mRNA and protein
expression in sub-populations of human peripheral blood mononuclear cells (PBMCs). LRRK2 mRNA and protein was found
in circulating CD19
+ B cells and in CD14
+ monocytes, whereas CD4
+ and CD8
+ T cells were devoid of LRRK2 mRNA. Within
CD14
+ cells the CD14
+CD16
+ sub-population of monocytes exhibited high levels of LRRK2 protein, in contrast to
CD14
+CD16
- cells. However both populations expressed LRRK2 mRNA. As CD14
+CD16
+ cells represent a more mature subset
of monocytes, we monitored LRRK2 expression after in vitro treatment with various stress factors known to induce
monocyte activation. We found that IFN-c in particular robustly increased LRRK2 mRNA and protein levels in monocytes
concomitant with a shift of CD14
+CD16
2 cells towards CD14
+CD16
+cells. Interestingly, the recently described LRRK2
inhibitor IN-1 attenuated this shift towards CD14
+CD16
+ after IFN-c stimulation. Based on these findings we speculate that
LRRK2 might have a role in monocyte maturation. Our results provide further evidence for the emerging role of LRRK2 in
immune cells and regulation at the transcriptional and translational level. Our data might also reflect an involvement of
peripheral and brain immune cells in the disease course of PD, in line with increasing awareness of the role of the immune
system in PD.
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Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disease affecting 1.5% of the population over 50 years
[1]. Recent studies have linked several genes with PD [1], although
the majority of PD cases is sporadic. Among associated genes,
Leucine-Rich Repeat Kinase 2 (LRRK2 alias Dardarin) stands out
since in some populations up to 30% of all PD patients carry the
G2019Smutation[2]. LRRK2is a largeandcomplex 2,527 amino-
acid protein that contains a ROC-COR domain with GTPase
activity and a kinase domain with homology to MAPKKKs.
Overall, biological functions of LRRK2 remain largely unknown,
and the identification of physiological substrates remains contro-
versial [3]. Nevertheless, there is consensus that LRRK2 multi-
merizes,auto-phosphorylates,andexistspredominantlyina dimeric
conformation when active [4].
Disease-associated mutations are localized in the ROC-COR
and kinase domains, but not all result in modification of GTPase
or kinase activities, leaving the pathogenic mechanism of such
mutations unresolved [3]. It has been reported that the LRRK2
I2020T mutation is associated with enhanced intracellular
degradation [5]. Studies performed in Caenorhabditis elegans or
Drosophila, as well as recent studies using bacterial artificial
chromosome (BAC) transgenic mice suggest that mutations in
LRRK2 disturb the dopaminergic system, i.e. decrease dopamine
release and cause motor deficits [6–7]. Since LRRK2 deficient [8]
or LRRK2 wt over-expressing [9] transgenic mice do not present
severe clinical neurological symptoms it seems likely that
pathological mutations are not associated with a simple gain or
loss of kinase or GTPase activity (for review [10]).
In general, these studies rely on artificially over-expressing or
knocking down LRRK2 expression. Since LRRK2 is thought to
be a stress kinase [11], and therefore can be expected to be tightly
regulated, we believe it is important to study its function and
regulation at endogenous levels. Due to its pathophysiological role
in PD, the major focus to date was to study LRRK2 function in
the brain. However, mRNA analysis revealed that LRRK2 is also
highly expressed in peripheral organs such as kidney, lung, spleen
and peripheral blood mononuclear cells [12–13]. The expression
of LRRK2 in immune cells [14–15] supports the idea that
LRRK2 could play a role in B cell development.
In contrast to neuronal cells, human PBMCs are easily
accessible and present a valuable source for studying LRRK2
biology. The current work describes the characterization of a
human PBMC sub-population expressing LRRK2 and the
regulation and stabilization of LRRK2 by IFN-c at the mRNA
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inhibitors suggest that LRRK2 may play an important role in
monocyte responses to IFN-c. From a clinical perspective our data
suggest that hPBMC and more specifically monocytes derived
from hPBMCs might yield biomarkers for therapeutic LRRK2
inhibitors.
Materials and Methods
Reagents
Differentinducersofcellularstressand cytokineswereused inthis
study: recombinant Human IFN-c, TNF-a, IL-1b, IGF-1 (R&D
Systems GmbH, Minneapolis, MN), LPS (from E. coli O111:B4,
Sigma-Aldrich, St. Louis, MO), and H2O2 (Sigma-Aldrich, St.
Louis, MO).
Several LRRK2 inhibitors were used: H1152 (Toronto
Research Chemicals Inc., Ontario Canada), Sunitinib (Sellek
Chemicals, Texas, USA), K252a (Sigma-Aldrich, St. Louis, MO),
Y27632 (Tocris Bioscience, Bristol, UK) and IN-1 (Generous gift
from Dr. D. Alessi, College of Life Science, University of Dundee,
Dundee, UK).
Antibodies
Three different antibodies against LRRK2 were used in this
study. Rabbit polyclonal antibody to LRRK2 (ref. ab60937) was
purchased from Abcam (Cambridge, UK), rabbit polyclonal
antibody to LRRK2 (AT106) from Alexis Biochemicals (Enzo
Life Sciences Inc., Plymouth Meeting, PA) and rabbit monoclonal
antibody to LRRK2 (clone MJFF3-c69-6) from Epitomics
Inc.(Burlingame, CA).
Mouse monoclonal antibody anti-Actin (clone C4) was from
Merck-Millipore (DE). Mouse monoclonal antibody anti-GAPDH
(6C5) was from HyTest Ltd (Turku, FI). Mouse monoclonal
antibody anti-Hsp70 (Hsp72, C92F3A-5) was from StressgenH
(Enzo Life Sciences Inc., Plymouth Meeting, PA).
For chemiluminescence Western blotting, goat polyclonal
antibody anti-Rabbit IgG/HRP was from Bio-Rad Laboratories
(Hercules, CA) and goat polyclonal antibody anti-Mouse IgG/
HRP from DakoCytomation (Carpinteria, CA). IRDyeH 680
donkey polyclonal antibody anti-mouse IgG and IRDyeH 800CW
donkey polyclonal anti-Rabbit IgG were from LI-COR Biosci-
ences (Lincoln, NE).
For FACS analysis, mouse anti-human CD3 FITC, CD4 FITC
or PE, CD8 PE, CD14 FITC, PE, PerCP-Cy5.5 or APC, CD16
FITC, CD19 FITC, HLA-DR APC, CD40 FITC, anti-CD54 PE,
CD62L FITC, CD68 PE, CD71 APC, CD80 FITC, CD83 PE,
CD103 FITC, CD206 PE and isotypes control (FITC mouse
IgG1k, PE mouse IgG2ak and APC mouse IgG2ak) were
purchased from BD Biosciences (Franklin Lakes, NJ). Mouse
anti-human CD16 APC was from InVitrogen Ltd (Paisley, UK).
Isolation of human peripheral blood mononuclear cells
Buffy-coats were obtained from anonymous blood donors via
Geneva Transfusion Center (HUG, Geneva, Switzerland). The
present study was approved by Merck Serono institutional
committee of scientists, and by a Merck Serono Biosafety
committee in charge to guarantee the correct use of the human
material, accordingly to ethical and safety rules.
Human peripheral blood mononuclear cells (PBMC) were
prepared from Buffy-coats.
Briefly, the blood sample was first diluted twice in sterile PBS
and overlaid onto Ficoll-Paque PLUS (GE Healthcare, Piscat-
away, NJ) and spun at 400 g for 20 minutes at room temperature
without brake. PBMC were collected at the plasma/Ficoll
interface and washed third with PBS. Quality of the preparation
was assessed by cell counting using a Coulter ACT-5 machine
(Beckman Coulter Inv., Fullerton, CA).
Isolation of human PBMC sub-populations
Depending on the type of experiment, human PBMC sub-
populations were isolated from fresh PBMCs using cell sorting or
immuno-magnetic beads (MACS
TM, Miltenyi Biotec). After
MACS separation, cell subpopulations were stained for flow-
cytometric analysis using combinations of fluorochrome-conjugat-
ed MAbs.
Isolation by FACS. Human PBMC were incubated with
normal mouse IgG (InVitrogen Ltd, Paisley, UK) for 15 min at
4uC to block Fc-mediated unspecific binding and labeled with
appropriate mouse monoclonal antibody anti-human CD for 1 h
at 4uC. Washing were performed with PBS, 0.1% BSA (Albumin
from Bovine Serum, Sigma-Aldrich, St. Louis, MO) and 0.01%
NaN3 (sodium azide, Sigma-Aldrich, St. Louis, MO). Cells were
sorted using a FACSAria cell sorter (Becton Dickinson, San Jose,
CA).
Isolation with immunomagnetic beads. CD14
+CD16
6
monocytes were purified from human PBMC by negative selection
using human monocytes enrichment kit without CD16 depletion
(19058, StemCell Technologies, Ko ¨ln, DE).
Monocyte sub-population CD16
- was obtained by two different
ways:
- Negative selection of CD14
+CD16
6 monocytes using
human monocytes enrichment kit (19059, StemCell Tech-
nologies, Ko ¨ln, DE).
- Negative selection of CD14
+CD16
6 monocytes using APC
selection kit with APC anti-human CD16 antibody (18451,
StemCell Technologies, Ko ¨ln, DE).
CD16
+ monocytes were obtained by positive selection.
Sub-populations obtained with StemCell methods were ana-
lyzed by flow cytometer for CD14 and CD16 expression, in order
to evaluate their purity.
Flow cytometry analysis
Cells were incubated with normal mouse IgG (Invitrogen Ltd,
Paisley, UK) for 15 min at 4uC to block Fc-mediated non-specific
binding and labeled with appropriate conjugated antibodies for
1 h at 4uC. Washing was performed with PBS, 0.1% BSA
(Albumin from Bovine Serum, Sigma-Aldrich, St. Louis, MO) and
0.01% NaN3 (sodium azide, Sigma-Aldrich, St. Louis, MO).
Staining with anti-CD68 PE was performed after fixation and
permeabilization with BD Cytofix/CytopermTM kit ((BD). Cells
were analyzed using a FACSCalibur flow cytometer (Becton
Dickinson, San Jose, CA). One hundred thousand events were
acquired for each sample. Data were analyzed using FlowJo 7.6
software (Tree Star, Ashland, OR) and results were expressed as a
percentage of total cells.
Cells cultures and treatment
Two millions of freshly prepared hPBMC or monocytes
CD14
+CD16
6 subpopulations were plated immediately in 2 mL
of RPMI 1640 medium (InVitrogen Ltd, Paisley, UK) supple-
mented with 10% FBS (HyClone Laboratories), penicillin/
streptomycin (InVitrogen Ltd, Paisley, UK), NEAA (InVitrogen
Ltd, Paisley, UK), 1 mM Sodium Pyruvate (InVitrogen Ltd,
Paisley, UK) in 6 wells cell culture cluster (Costar, ref 3516) at
37uC in a humidified atmosphere containing 5% CO2. In some
experiment (specified in text) cells were kept over-night at 4uCi n
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IGF-1, IL-6, LPS, H2O2 were diluted in PBS and directly added at
plating time in the culture medium for 24 h. After being
solubilized in 100% DMSO (Sigma-Aldrich, St. Louis, MO),
LRRK2 inhibitors were added directly into the culture medium
15 min before IFN-c treatment. The final concentration of
DMSO was of 0.1%. Unless specified in the text, cells were
collected 24 h after plating.
Monocyte maturation towards dendritic cells and
macrophage phenotypes
Two millions CD14
+ CD16
6 monocytes were plated in 2 mL of
culture medium supplemented with 50 mM 2-mercaptoethanol
(Sigma-Aldrich, St. Louis, MO), 100 ng/ml (100 IU/ml) recom-
binant human IL-4 (ImmunoTools, Friesoythe, D) and 100 ng/ml
(100 IU/ml) recombinant human GM-CSF (ImmunoTools,
Friesoythe, D) for dendritic cells phenotypes and with 20 ng/ml
LPS (from E.coli O111:B4, Sigma-Aldrich, St. Louis, MO) for
macrophage phenotypes. Cells were incubated at 37uCi na
humidified atmosphere containing 5% CO2. The cultures were fed
with fresh complemented culture medium with cytokines or LPS
every 2 days. After 7 days, cells were harvested and analyzed by
FACS with a direct staining (FITC anti-CD83, PE anti-CD80,
PerCP Cy5.5 anti-CD14, APC anti-CD16 and FITC anti-CD103,
PE anti-CD206, PerCP-Cy5.5 anti-CD14, APC anti-CD16, FITC
anti-CD40, PE anti-CD68, APC anti CD71. For LRRK2
expression analysis by Western blot cells were lysed as described
in the following section.
Western blot analysis
Freshly purified cells were lysed using RIPA buffer comple-
mented with protease inhibitor (Roche Diagnostics, Indianapolis,
IN) and phosphatase inhibitor cocktail (Thermo Scientific, Rock-
ford, IL). Samples were sonicated then centrifuged at 13,000 g for
15 min at 4uC. Supernatants were collected and kept at -20uC
until use. For in vitro experiments, hPBMC or CD14
+CD16
6
adherent and non-adherent cells were collected separately at the
end of the experiment. Non-adherent cells were removed directly
from culture medium by centrifugation and washed once with ice-
cold PBS. Adherent cells were collected after being washed twice
with cold PBS containing 1 mM of EDTA. Cell pellets were
thereafter treated as freshly purified cells. After protein determi-
nation using Pierce BCA (Thermo Scientific, Rockford, IL), 25 mg
of protein was separated on NUPAGEH Novex 3–8% Tris-Acetate
Gel (InVitrogen Ltd, Paisley, UK) or 10–20% Tris-Glycine Gel
(InVitrogen Ltd, Paisley, UK) and transferred to nitrocellulose
membrane (InVitrogen Ltd, Paisley, UK). Membranes were
blocked using 5% non-fat powdered milk (Rapilait, Migros,
Switzerland) in PBS buffer containing 0.1% Tween 20 (Merck
KGaA, Darmstadt, Germany) for chemiluminescence and with
OdysseyH blocking buffer (LI-COR Biosciences, Lincoln, NE) for
fluorescence. The membrane was incubated overnight at 4uC with
primary antibody. After rinsing in PBS containing 0.1% Tween
20, membranes were incubated with secondary antibody for 2 h at
room temperature, processed with an enhanced chemilumines-
cence detection system (Amersham Biosciences, GE healthcare,
little Chalfont, UK) or directly scanned with the infrared
OdysseyH imaging system (LI-COR Biosciences, Lincoln, NE).
The level of expression of each protein was quantified from
scanned images using Odyssey software with average top/bottom
background method and fluorescence converted in integrated
intensities. The protein signal was normalized with the signal of
actin.
Quantitative reverse-transcription polymerase chain
reaction (qRT-PCR)
Freshly isolated cells or cells maintained in culture for 3, 6 or
24 h of induction cells were washed twice with cold PBS and total
RNA was prepared with TRIzol Reagent (InVitrogen 15596)
using the manufacturer’s protocol. 2 mg total RNA was used as
template for reverse transcription with qScript cDNA SuperMix
5x (#95048-100 Quanta). cDNA was then diluted 30x and real-
time PCR reactions were performed in triplicates using FastStart
Universal SYBR Green Master mix (ROCHE #04913914001)
and the QuantiTectH primer assays from QIAGEN (Figure S1).
Statistical analyses
A two-tailed unpaired t-Test was used for comparison between
two groups. For experiments with more than two conditions, data
were analyzed using one-way analysis of variance (ANOVA) using
GraphPad Prism 5. For all analyses, a two tailed test was employed
and a Bonferroni’ multiple comparison test used as post test.
Statistical significance was established at a P,0.05. Data are
presented as mean 6 standard deviation (SD).
Results
LRRK2 expression in hPBMC and hPBMC sub-populations
Recent publications and expression database analyses highlight
the fact that LRRK2 mRNA is abundantly expressed in spleen
and B lymphocytes [12,14]. In this study we further evaluated
LRRK2 expression in PBMCs at the mRNA and protein levels.
We detected a robust LRRK2 mRNA signal in hPBMCs as
compared to various cell lines studied (Fig. 1A).
LRRK2 expression in circulating B lymphocytes has recently
been described [14–15]. To explore if B cells are the only blood
cells expressing LRRK2, we studied its expression on isolated
PBMC sub-populations (Fig. 1B). PBMC sub-populations were
isolated by FACS based on the expression of CD markers and
analyzed by qPCR for LRRK2 and LRRK1 expression. First, we
confirmed expression of LRRK2 in circulating B cells (CD19
+). In
B cells, LRRK2 was expressed slightly higher in C19
+CD27
+ than
in CD19
+CD27
2 cells (data not shown). In contrast, CD3
+, CD4
+
and CD8
+ cells representing T cell populations demonstrated
very low levels of LRRK2 mRNA. LRRK1 mRNA was found also
at very low levels in hPBMCs, and generally in all of the
subpopulations investigated. The monocyte population that
expressed the LPS co-receptor CD14 revealed high levels of
LRRK2 mRNA.
LRRK2 expression was also studied at the protein level
(Fig. 1C). The identity of the LRRK2 immunoreactive band was
established using three different LRRK2 antibodies (Figure S2).
To further document LRRK2 expression in monocytes subpop-
ulations, monocytes were separated accordingly to the low-affinity
FccRIII receptor (CD16) expression (see Figure S3 for FACS
profile). In B- or T-lymphocytes LRRK2 protein levels matched
LRRK2 mRNA levels, confirming LRRK2 protein expression by
B-lymphocytes. For CD14
+ monocytes we observed a striking
difference in LRRK2 protein expression in CD14
+CD16
+ as
opposed to CD14
+CD16
- monocytes. Both subsets expressed
similar levels of LRRK2 mRNA (Figure 1D) but CD14
+/CD16
+
cells were found to contain 14.166.2 times more (p,0.01, n=3,
Student t-Test) LRRK2 protein than CD14
+/CD16
2 cells, where
LRRK2 is almost not detectable. This difference between protein
levels was confirmed with all three tested antibodies (Figure S2)
and was observed whether cells were isolated by FACS (2
independent experiments) or by immunomagnetic beads (3
independent experiments). Furthermore qPCR analysis of these
LRRK2 Regulates Monocyte Response to IFN-c
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+CD16
2 and CD14
+CD16
+ populations confirmed the lack
of contamination by CD3
+, CD19
+ or CD56
+ cells (Figure 1D).
Induction of LRRK2 expression in hPBMC
The proportion of CD14
+CD16
+, now referred as nonclassical
monocytes is increased during inflammatory conditions and these
cells are considered to be more mature than CD14
+CD16
2
monocytes [16–17]. Since it was previously suggested that LRRK2
belongs to a family of stress-activated kinases [11] we next tested
whether LRRK2 protein and mRNA expressions were modulated
during induced stress, or during monocyte activation. In order to
evaluate expression within a ‘‘native" environment that allows
potential cross-talk between various PBMC sub-types we first
studied LRRK2 induction in hPBMC preparations. We explored
a wide range of inducers of cellular stress and cytokines, such as
storage at 4uC, H2O2, LPS, IFN-c, IFN-b, TNF-a, IL-1b, IL-6,
IL-2, IL-15 and IGF-1. Of those tested, only few led to a robust
and consistent increase of LRRK2 levels as assessed by qPCR and
Western blot (Table 1, Fig. 2 and Figures S4 and S5).
In the stress inducing category, we found that keeping PBMCs
overnight at 4uC in PBS solution led to a robust .5-fold increase
(p,0.01, n=5) of LRRK2 mRNA (Fig. 2A) and protein (Fig. 2B)
as compared to freshly prepared hPBMCs. Interestingly, 24 h after
plating LRRK2 levels were back to the level found in freshly
isolated cells (Fig. 2B).
Since cytokines and interferons are major players in monocyte
activation we next tested their potential to increase LRRK2
expression in hPBMCs. IFN-c treatment increased LRRK2
mRNA and protein expression respectively by 11.463.5 fold
(p,0.005, n=6) and 6.262.1 fold (p,0.005, n=5; Fig. 2C, 2D).
This was dose- (Fig. 2C) and time dependent with a peak of
mRNA expression at 6 h (n=3, Figure S4). Other molecules such
as IFN-b, TNF-a or IL-6 also induced LRRK2 albeit only to a
modest degree and with donor-to-donor variation (Table 1 and
Figure 1. LRRK2 mRNA and protein expression in hPBMC subpopulations. (A) LRRK2 mRNA expression in various cell types showing higher
expression level in hPBMCs. (B) LRRK2 (black bars) and LRRK1 (grey bars) mRNA expression in hPBMC sub-populations. hPBMC sub-population were
purified by FACS based on their cell surface markers: Monocytes (CD14
+), B lymphocytes (CD19
+) and T-lymphocytes (CD3
+, CD4
+ or CD8
+).
Expression level was performed on freshly isolated cells and the graph represents a pool of at least three independent experiments. LRRK2 and LRRK1
mRNA amounts were normalized to average values of three housekeeping genes namely GAPDH, HMBS and actin B (% HKG). LRRK2 mRNA quantities
in hPBMC sub-populations were compared to LRRK2 mRNA values in total hPBMC (** p,0.01, n=3, One-way-Anova with Bonferroni post test). (C)
Representative western-blot of five independent experiments using ab60937 antibody from (Abcam) confirming LRRK2 protein expression in hPBMC
sub-populations with striking enrichment in the CD14
+CD16
+ monocyte sub-population as compared to CD14
+CD16
2 monocytes. Similar results
were obtained with two other antibodies against LRRK2 (Cf. Figure S2). Molecular size markers are indicated on the left in kilo Dalton (kDa). (D) LRRK2,
LRRK1 and PBMC subtype mRNA expression in purified sub-populations. Graph represents a pool of two independent experiments. Note the identical
level of LRRK2 mRNA in CD14
+CD16
2 and CD14
+CD16
+ monocytes. CD3, CD14, CD16 and C56 mRNA level were used to assess the enrichment
efficacy. mRNA amounts were normalized to average values of three housekeeping genes (% HKG).
doi:10.1371/journal.pone.0021519.g001
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IGF-1 did not induce LRRK2. Of note, none of the treatments
described above significantly induced LRRK1 mRNA expression
(Figure S5).
It has been reported previously that IFN-c treatment provokes
adhesiveness of monocytes and a switch in the CD14
+CD16
+/
CD14
+CD16
2 ratio whereas non-activated monocytes, NK, B
and T cells remain in suspension [18]. We used this phenomenon
to further explore which cells induce LRRK2 expression after
IFN-c stimulation. In our experiments at plating time the
monocyte (CD14
+) population represented 15–20% of the total
plated cells. At this moment only a quarter of these monocytes
were CD16
+. Twenty four hours after IFN-c treatment, 60-80% of
adherent cells were monocytes and two-thirds of them CD16
+
(Fig. 3A). In adherent cells the increase of LRRK2 protein levels
was very significant (Fig. 3B) and paralleled the adhesion of almost
90% of CD14
+ cells (Fig. 3A). These adherent cells corresponded
to the population of activated monocytes as assessed by high
ICAM-1 (CD54), low L-selectin (CD62L) and a shift in co-
stimulatory ligand for T cells activation (CD80) co-expression with
CD14 and CD16 markers (Figure S6). Therefore the IFN-c -
induced LRRK2 protein expression paralleled monocytes adhe-
sion and switch towards CD16 expression. In contrast to IFN-c,
IGF-1 and IL-1b did not induce LRRK2 expression in adherent
or non-adherent populations (Fig. 3B).
LRRK2 expression by maturating monocytes,
macrophages and dendritic cells
To establish if the induction of LRRK2 expression by
CD14
+CD16
+ cells in response to IFN-c was due to a direct or
indirect effect of IFN-c on CD14
+ cells, we purified CD14
+
populations and treated them with IFN-c. We found that on
purified monocytes the IFN-c-induced shift of CD14
+CD16
- to
CD14
+CD16
+ monocytes (Fig. 4A) was indeed accompanied by an
increase in LRRK2 mRNA and protein expression (Fig. 4B, C) by
respectively 1364( p ,0.005, n=3) and 17.569.8 (p,0.01, n=4)
fold. Another condition known to directly activate monocytes is to
plate cells in serum-free media. In these conditions monocyte
activation was also associated with a significant increase of
LRRK2 protein expression in adherent cells (Figure S7).
These experiments suggest that LRRK2 mRNA and protein are
expressed during monocyte activation. As blood monocytes
represent an intermediate population that differentiates into either
macrophages or dendritic cells [19–20], we also studied LRRK2
expression during in vitro maturation ofmonocytestowards dendritic
cells and macrophages. The purified CD14
+ monocyte population
was cultured for one week in presence of GM-CSF/IL-4 or LPS to
generate dendritic cells and macrophages respectively. Monocyte
differentiation was assessed by FACS determination of macrophage
and dendritic cells markers (Figures S8 and S9) such as CD40, a
costimulatory protein found on antigen presenting cells CD68, a
glycoprotein binding to low density lipoprotein, transferrin receptor
protein 1 (TfR1) also known as CD71, T-activation co-stimulatory
factor (CD80), Sialic acid binding Ig like adhesion receptor (CD83),
Integrin aE (CD103) and Macrophage Mannose Receptor
(CD206). High levels of LRRK2 protein were detected in both
dendritic cells and macrophages (Fig. 4D) suggesting that LRRK2
protein levels remains elevated during the maturation process.
Altogether these data revealed the modulation of LRRK2
mRNA and protein levels by IFN-c and the preferential expression
of LRRK2 protein by CD14
+CD16
+ monocytes and by matured
DCs and macrophages.
LRRK2 inhibition decreases CD14, CD16 and MHC-II
expression by monocytes
Because the IFN-c -induced LRRK2 increase in monocytes
paralleled the switch toward CD16
+ cells, we explored the effect of
kinase inhibitors active on LRRK2. The most selective inhibitor
described to date is IN-1 with an IC50 of 13 nM on LRRK2 wt
kinase activity inducing a complete dephosphorylation of LRRK2
Table 1. Effect of various cytokines and stress conditions on LRRK2 expression in hPBMCs.
Tested molecule
IFN-c (30 IU/mL) IFN-b (100 IU/mL) TNF-a (10 ng/mL) IL-6 (10 ng/mL)
LRRK2 protein Increase Increase Increase Slight increase
Confirmed 20x/23 expts 2x/2 expts 5x/7 expts 2x/4 expts
LRRK2 mRNA Increase Increase Increase ND
Tested molecule
IL-1b (25 ng/mL) IL-15 (10 ng/mL) IL-2 (10 ng/mL) IGF-1 (25 ng/mL)
LRRK2 protein No effect No effect No effect Slight decrease
Confirmed 3x/4 expts 2x/2 expts 1x/1expt 2x/3 expts
LRRK2 mRNA No effect ND ND No effect
Tested molecule
46C Overnight Serum free H2O2 (30 mM) LPS (50 ng/mL)
LRRK2 protein Increase Increase Increase? Decrease
Confirmed 5x/5 expts 3x/3 expts 2x/5 expts 4x/7 expts
LRRK2 mRNA Increase ND ND No effect
Freshly prepared hPBMCs were cultured under various conditions for 24 h. LRRK2 protein expression was monitored by Western blot and qPCR. As hPBMC population
composition may vary by donor, the number of times where a given result was found as well as the total number of experiments (expts) performed are indicated.
Results are only qualitatively represented. Corresponding qPCR data and western blots and are shown in Figures S4 and S5. IFN-c, IFN-b and to a lesser extent TNF-a
were very potent inducers of LRRK2 expression at both the protein and mRNA level. ND: Not determined.
doi:10.1371/journal.pone.0021519.t001
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different chemical families (Table 2), which all have in common to
inhibit LRRK2 kinase activity, but differ in their kinase selectivity
profile and potency towards LRRK2 kinase inhibition.
Twenty four hours after plating in presence of LRRK2
inhibitors and IFN-c cells were collected and stained for CD14,
CD16 and MHC-II expression and analyzed by FACS (Figure
S10). IN-1, the most selective inhibitors tested [21,22], dose-
dependently blocked the CD14
+ (Fig. 5A) and CD16
+ (Fig. 5B)
switch in response to IFN-c treatment (Table 2). Effects of IN-1 on
CD16 expression were still very significant at 1 mM( p ,0.005), a
concentration at which IN-1 is believed to be quite selective. These
effects on CD14
+ and CD16
+ switch were confirmed with two
other very potent LRRK2 inhibitors namely K252a and Sunitinib
that have an IC50 of respectively 4 nM and 79 nM [22]. Indeed, at
10 mM not only IFN-c effects were fully blocked (p,0.005 for all
three inhibitors) but also the percentage of CD16
+ cells dropped
below untreated values (p,0.01 for all three inhibitors). At 10 mM,
MHC-II expression was also attenuated by these inhibitors
(p,0.01 for IN-1, p,0.005 for K252a and Sunitinib; Fig. 5C,
Table 2). In contrast, H1152 (IC50: 244 nM) and Y27632 (IC50:
2,300 nM) two inhibitors with 20-100 -fold lower potency on
LRRK2 than IN-1 had no effect on IFN-c-induced monocyte
maturation (Fig. 5A, B, C and Table 2).
In order to ascertain that the used inhibitors were not just
shunting IFN-c responses we looked at several proteins known to
be induced by IFN-c as well as at LRRK2 mRNA induction by
IFN-c. None of the tested inhibitor blocked IFN-c-induced Hsp70
expression by monocytes (Fig. 6A) nor prevented LRRK2 mRNA
induction in hPBMC (Fig. 6B). The compounds also did not affect
cell viability as assessed by Alamar Blue tests at 24 h (Fig. 6C).
Discussion
Autosomal-dominant mutations in LRRK2 alias Dardarin
significantly raise the risk of familial PD, and the G2019S
Figure 2. Induction of mRNA and protein LRRK2 expression in hPBMCs. (A) LRRK2 and LRRK1 mRNAs from freshly isolated hPBMCs or
hPBMCs kept overnight at 4uC were quantified by qPCR (5 independent experiments). (B) Western-blot confirming LRRK2 protein induction by
hPBMCs overnight storage at 4uC. One day after plating (1 DIV) LRRK2 protein is back to initial value. (C, D) IFN-c induced LRRK2 expression in
hPBMC. PBMCs were cultured for 24 h in presence of various amount of IFN-c (0.1, 10 and 100 IU/mL) and analyzed for LRRK2 mRNA (C, n=3) and
protein (D, n=4) expression level. PBMC refers to freshly prepared hPBMC and control refers to PBMC cultured for 24hrs in absence of stimulus. Actin
protein was used as internal control for equal loading. LRRK2 and LRRK1 mRNA amounts were normalized for housekeeping genes (% HKG). Statistical
difference in normalized LRRK2 or LRRK1 mRNA amounts were calculated against values obtained from freshly isolated cells (* p,0.05; ** p,0.01;
***, p0.005, Student t-Test for (A), One-way-Anova with Bonferroni post test for (C).
doi:10.1371/journal.pone.0021519.g002
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21519Figure 3. IFN-c induced expression of LRRK2protein in CD14
+ monocytes. Twenty four hours after plating with or without cytokines,
adherent and non-adherent hPBMCs were separately collected and processed for FACS analysis for CD14 and CD16 populations (A) and Western-blot
analysis for LRRK2 protein level (B). (A) Percentage of CD14
+ adherent cells was calculated as the ratio of panel (a+b)/((a+b)+(c+d)) for each condition.
Percentage of CD16
+/CD14
+ adherent cells was calculated as the ratio of a/(a+b) for each condition. The arrow highlights the very strong shift of cells
toward a CD14
+ CD16
+ population after IFN-c treatment (30 IU/mL). (B) Effect of IFN-c (30 IU/mL) or IFN-b (100 IU/mL) on LRRK2 expression is
restricted to adherent cells population (mainly constituted of CD14
+ cells). By contrast, IGF-1 (25 ng/mL) or IL-1b (25 ng/mL) had no effect on LRRK2
expression. Actin protein was used as loading control. Representatives western blot of three independent experiments.
doi:10.1371/journal.pone.0021519.g003
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21519Figure 4. LRRK2 expression by maturating monocytes, macrophages and dendritic cells. (A) Purified CD14
+ monocytes were treated with
IFN-c (30 IU/mL) for 24 h and cells analyzed by FACS to assess CD14 and CD16 expression levels. (B) and (C) The observed shift towards CD14
+CD16
+
cells observed in (A) paralleled an increase in LRRK2 mRNA and protein levels as revealed by qPCR (n=3) and Western blot (n=4) (***, p,0.005,
Student t-Test). (D) LRRK2 expression persists in monocytes-derived dendritic cells (DC) and macrophages (MF) matured 7 days in vitro with IL-4/GM-
CSF (dendritic cells) or LPS (macrophages). Cell type was assessed by FACS analysis of CD markers (Cf. Figures S8 and S9). Representative western blot
of at least 3 independent experiments are shown.
doi:10.1371/journal.pone.0021519.g004
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functional consequences of these mutations remain largely
unknown and most of the available data have been generated
using artificial systems based on ectopic expression of wild-type
LRRK2, or LRRK2 mutations associated with PD.
In the present study, we explored LRRK2 expression in
hPBMC. By sub-fractionating PBMCs two cell populations
expressing LRRK2 protein were identified namely B cells
(CD19
+) and a sub-set of monocytes (CD14
+CD16
+). In contrast,
T cell (CD3
+, CD4
+, CD8
+) and NK cell (CD3
-CD14
-CD16
+)
populations did not express LRRK2. These results are partially in
agreement with recent data published [14], where a strong
expression of LRRK2 in CD19
+ splenic cells and a lack of
expression in CD3
+ cells were described. Interestingly, in this study
a weak expression in CD11b
+ splenic cells (a CD marker for
macrophages but also other cell types e.g. neutrophils and NK
cells) was described, whereas we found a robust expression of
LRRK2 protein in CD14
+CD16
+ circulating cells but not in
CD14
+CD16
2 cells.
We did not found differences between LRRK2 mRNA levels in
CD14
+ CD16
2 and CD14
+ CD16
+ subsets. We further document
our finding by a search on the transcriptome analysis of CD14
+
CD16
- versus CD14
+ CD16
+ cells by Ingersoll et al. [23]. Their
transcriptome data confirmed that LRRK2 mRNA level is similar
in these two sub-populations (Figure S11). As we found a
differential LRRK2 protein expression using three distinct
antibodies, we believe that this difference between LRRK2
mRNA and LRRK2 protein is real. Whether it reflects a lack of
translation of LRRK2 mRNA or a lack of LRRK2 protein
stabilization in CD14
+ CD16
2 cells remains to be elucidated. In
contrast to what we have seen in CD14
+ CD16
2 monocytes, in B-
lymphocytes high LRRK2 mRNA level was reflected by a high
LRRK2 protein level.
There are further subsets of CD14
+ monocytes that are dis-
tinguished by their CD16 expression levels. There is a develop-
mental relationship between these three subsets, as classical (CD14
+
CD16
2) matured towards noncalssical (CD14
+/CD16
++)v i aa n
intermediate stage (CD14
++CD16
+) [17]. Nonclassical monocytes
represent less than 10% of the monocyte population in hPBMCs
and are perceived as crucial in inflammation and infectious diseases
in man. Indeed CD14
+CD16
++ monocytes have higher levels of
HLA-DR [24] and display higher antigen presenting cell (APC)
activity than CD14
+CD16
2 cells (for review see [25,16]). Several
publications showed that CD14
+CD16
++ preferentially develop into
dendritic cells [26] and produce higher level of TNF-a and IL-1
than CD16
- monocytes [27–28]. In the current study we did not
separate the two subsets of CD16
+ monocytes (CD14
++CD16
+
versus CD14
+CD16
++) and therefore will only talk about
CD14
+CD16
+ and CD14
+CD16
2 monocytes subpopulations. In
future studies to resolve the role of LRRK2 it might be worth to
distinguish these two subsets.
The difference we observed between LRRK2 levels in
monocyte sub-types suggests that LRRK2 expression is regulated
during the monocytes/macrophages life cycle. The finding that
plating PBMCs in serum-free media (a classical paradigm to
activate monocytes) induced LRRK2 expression strengthens this
idea. Expression of LRRK2 by dendritic cells and macrophages in
Crohn’s disease patients has recently been reported [29]. Our in
vitro maturation experiments confirm the observation that
maturation of monocytes towards DC or macrophages is
accompanied by LRRK2 expression. Finally, recent data showing
that pre-B, B1 and B2 subtypes of B-lymphocytes express different
levels of LRRK2, indicate that LRRK2 expression is also
regulated during B cell maturation [15]. Overall, ours as well as
others’ data point to a role of LRRK2 in cell differentiation and
cell fate of B lymphocytes and monocytes lineage.
The second key point of this study is the demonstration that
IFN-c induces of LRRK2 expression in hPBMC, and more
specifically in isolated monocytes. Gardet et al., [29] also reported
that IFN-c could induce LRRK2 expression on hPBMC and
THP-1 cells. In the current study we confirmed these finding and
demonstrate that IFN-c-induced increase of LRRK2 levels in
hPBMCs was attributable to adherent CD14
+ cells since in non-
adherent cells mostly composed of CD4
+, CD8
+, CD19
+ and
CD3
-CD14
-CD16
+ cells no increase of LRRK2 was detected. The
similarity between this study and ours, especially regarding the
amplitude of the induction, is striking and strongly confirms
control of LRRK2 expression by IFN-c. However, we did not
detect LRRK2 expression in T lymphocytes whether or not they
were treated with IFN-c. This lack of LRRK2 expression by T
lymphocytes is in accordance with Maekawa’s observations [14].
IFN-c signaling is a gate-keeper of the innate immune system
and its ability to activate monocytes is well documented. For
example, IFN-c induces monocytes to express several markers of
Table 2. Effect of LRRK2 inhibitors on IFN-c-induced expression of CD14, CD16 and MHC-II by monocytes.
%CD14+ cells %CD16+ cells %MHC-II+ cells
CTRL + DMSO 0.1% ND 31±12 22±12 31±20 n=8
INF-c + DMSO 0.1% ND 80±5
c 65±11
c 75±8
c n=8
Enzyme %CD14+ cells @ %CD16+ cells @ %MHC-II+ cells @
IC50 (nM) 1 mM1 0 mM1 mM1 0 mM1 mM1 0 mM
INF-c + K252a 4 50±10
a 0.4±0.3
c 45±81 ±1
c 31±11
c 19±5
c n=3
INF-c + 1N-1 13 76±23 2 ±7
c 10±3
c 3±1
c 56±54 7 ±10
c n=4
INF-c + Sunitinib 79 79±69 ±6
c 79±97 ±5
c 53±14 18±7
c n=4
INF-c + H-1152 244 72±14 76±13 63±15 63±13 66±15 68±15 n=5
INF-c + Y-27632 2300 67±18 67±17 61±23 61±21 54±10 59±16 n=3
For each inhibitor IC50 obtained on LRRK2 WT kinase enzyme activity is indicated (Deng et al., 2011; Nichols et al., 2010). Is indicated the percentage +/2 SD of CD14
+,
CD16
+ or MHC-II
high cells obtained after IFN-c treatment (30 IU/mL) in presence of 1 or 10 mM of LRRK2 inhibitors. In all experiment DMSO concentration has been fixed
to 0.1%. (
a p,0.05,
c p,0.005, One way Anova with Bonferroni post test). N indicates the number of independent experiment for each tested compound. ND: Not
determined.
doi:10.1371/journal.pone.0021519.t002
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our experiments LRRK2 induction paralleled CD14
+ and CD16
+
shift and MHC-II expression by monocytes. With respect to
LRRK2, IFN-c seems to have two different effects. First it induces
LRRK2 mRNA expression within few hours. This effect could be
due to a direct effect of IFN-c on LRRK2 transcription, and in
line with this notion we and others [29] found that the 59 region of
the LRRK2 gene contains several consensus interferon-stimulated
responsive elements (IRSE), and gamma activated sequences
(GAS) (Figures S12 and S13, [31]). It is interesting to note that
IRES and GAS sequences were not found in the first 2 kbp of the
LRRK1 gene promoter (Figure S14). Second, IFN-c is known to
induce HSP90 expression [32] and HSP90 might stabilize LRRK2
posttranslationally by preventing LRRK2 from CHIP mediated
proteasomal degradation as previously suggested [33,34,35]. Our
experiments with Geldanamycin confirmed that LRRK2 stabili-
zation is HSP90 dependent and that IFN-c induction of LRRK2
protein requires HSP90 (data not shown). It should be noted that
IFN-c is not the only inducer of LRRK2, indeed in our
experiments other stress conditions such as serum free culture or
addition of cytokines such as IFN-b or TNF-a, also induced
LRRK2 but in a more variable and weaker manner than IFN-c.
Figure 5. LRRK2 inhibition decreased IFN-c–induced CD14, CD16 and MHC-II expression by monocytes. Purified monocytes were
cultured in presence of various concentrations of LRRK2 inhibitors before stimulation with IFN-c. Twenty four hours later cells were collected and
analyzed by FACS for quantification of CD14 (A), CD16 (B) and MHC-II (C) expression levels. For details on FACS settings see Figure S10. Values are
expressed as the number of cells with a given phenotype (e.g. CD14
+, CD16
+ or MHC-II
high) versus the total number of cells analyzed. Data of several
experiments have been pooled and at least three independent experiments have been performed for each dose tested (for more details cf. Figure
S10 and Table-2). Most potent LRRK2 inhibitors (K252A, IN-1 and Sunitinib) induced a severe reduction of CD14 (A) and CD16 (B) expression by
monocytes meanwhile less potent inhibitors (H1152 and Y27632) had no effect. Inhibition of MHC-II expression (C) was also observed with best
LRRK2 inhibitors. (* p,0.05, ** p,0.01, ***p,0.005, One-way-Anova with Bonferroni post-test).
doi:10.1371/journal.pone.0021519.g005
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kinase inhibitors active on LRRK2 such as IN-1, K252a and
Sunitinib significantly attenuate the CD14, CD16 and MHC-II
shift in expression levels following IFN-c stimulation. These effects
are not due to a shunting of global IFN-c response since an
increase of Hsp70 expression and an induction of LRRK2 mRNA
were still observed in presence of these inhibitors. Two other
inhibitors, H1152 and Y27632, with much lower potency on
LRRK2 inhibition (20–50 times lower [21,22]) did not signifi-
cantly prevent monocytes differentiation. Such a difference
between LRRK2 inhibitors efficacy has also been described in
cellular assays assessing LRRK2 Ser910 phosphorylation [22,36].
Markedly, these publications also highlighted the fact that despite
their nanomolar activity on recombinant enzyme these inhibitors
were only active at low micromolar concentrations on cells. Even
with the most selective LRRK2 inhibitor IN-1, in cellular assays
complete dephosphorylation of LRRK2 ser910/ser935 was
observed at 1-3 mM. In this assay, the specificity of IN-1 was
assessed by using a drug resistant mutant LRRK2 (A2016T) [21].
There is no explanation for this significant shift in potency but it
might reflect compounds capability to enter the cells as well as
more complex considerations such as stability and metabolism.
With respect to selectivity the recently characterized inhibitor IN-1
appears much more selective while as potent as K252a and
Sunitinib [21] and represents therefore an important novel tool to
study LRRK2. Indeed it has been evaluated against a panel of
more than 470 kinases and to date DCLK2 is the only kinase with
an IC50 close to those of LRRK2. As in our assay IN-1 is as active
at 1 mM than at 10 mM in blocking CD16 expression, we are in a
same range of efficacy than what has been found in LRRK2
Ser910/Ser935 cellular assays and believe that our data most
probably reflect LRRK2 inhibition. Nevertheless, we keep in mind
that none of the other tested inhibitors is exclusively LRRK2
specific and the identification of more selective LRRK2 inhibitors
and the use of genetic approach are needed to confirm and extend
our findings.
The hypothesis that LRRK2 might be involved in monocyte
maturation echoes recent observations made by others. For
example, LRRK2 KO mice have a tendency to develop
splenomegaly [37]. This might reflect difficulties for immune cells
to mature and egress from spleen. It was also reported that B-
lymphoblastoid cell lines carrying LRRK2 mutations display
impaired growth [38] and that LRRK2 might be associated with
increased susceptibility to Crohn’s disease [39]. Transcriptional
profiling of PBMCs from G2019S LRRK2 PD patients revealed a
deregulation in leukocyte extravasation signaling and other
immune functions, including an up-regulation of IFN-c mRNA
[40].
The expression pattern of LRRK2 protein and its possible role
in immune cell maturation raise the question as to whether
LRRK2 constitutes a link between the immune system and
Parkinson’s disease. Indeed, there is increasing evidence of
immune components playing a role in Parkinson’s disease
progression. Invasion of T cells in the brain and modification of
the CD8
+CD4
+CD25
+ ratio have been reported in PD patients
[41–42]. Several inflammatory cytokines such as IL-2, IL-4, IL-6,
IL-10, TNF-a and IFN-c are up-regulated in sera of PD patients
[43-44] and association between systemic markers of inflammation
and idiopathic PD risk has been reported [45]. Interestingly,
increased presence of CD14
+CD16
+ cells is commonly associated
with inflammatory diseases such as Atherosclerosis, Kawasaki
disease or bacterial infection (for review see [16]) and LRRK2
participates to antibacterial responses [29]. In HIV patients with
encephalopathy, perivascular macrophages in the brain were
found to be CD14
+CD16
+ [46]. To our best knowledge there is no
study specifically assessing the role of CD14
+CD16
+ cells in PD
patients, but as these cells can switch to dendritic cells, they might
participate in initiation or enhancement of immune responses by
activating T cells. The recently discovered genetic association
between the HLA region with late-onset sporadic Parkinson’s
disease [47] strengthens the possible relevance of antigen
presenting cells in PD. Interestingly, Gottfried-Blackmore et al.,
[48] recently described a sub-population of microglia named brain
Figure 6. LRRK2 inhibitors were not shunting IFN-c induction.
hPBMC-derived monocytes were cultured for 24 h in presence of LRRK2
inhibitors plus IFN-c (30 IU/mL). Effect of IFN-c on monocytes was
assessed by monitoring the induction of Heat-shock protein Hsp70 by
western blot (A) and by quantifying LRRK2 mRNA by qPCR (B). LRRK2
inhibitors did not prevent Hsp70 or LRRK2 induction. (C) Effect of LRRK2
inhibitors (10 mM for each) on cell survival was monitored by Alamar
Blue 24 h after plating. Graphs represent an average of three
independent experiments. No statistical difference was found between
control (ctrl) and other groups (One-way-Anova, Bonferroni post test).
doi:10.1371/journal.pone.0021519.g006
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IFN-c by increasing MHC-II expression and induce CD4 T cells
to proliferate. Based on our findings, it will be worthwhile to study
the role of LRRK2 and its mutations in this context.
In conclusion, our study revealed a preferential expression of
LRRK2 protein but not mRNA in activated CD14
+CD16
+
monocytes. Monocytes activation by IFN-c was accompanied by
up-regulation of LRRK2 mRNA and protein levels in monocytes.
Using potent inhibitors of LRRK2 kinase activity, we also
provided evidence that LRRK2 signaling might be involved in
expression of cell surface markers associated with monocyte
maturation. Our data support previous observations on the
possible role of LRRK2 during immune cells maturation and
open the possibility to study LRRK2 kinase function in a "natural"
biological system. In addition our data might offer a functional
pharmacodynamics biomarker for LRRK2 inhibitors activity that
could complement measurement of Ser
910/Ser
935 phosphorylation
of LRRK2 as proposed by Dzamko et al. [36].
Supporting Information
Figure S1 Reference of qPCR primers used in this
study. Primers were obtained from QIAGEN. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), hydroxymethylbilane syn-
thase (HMBS) and Actin B were used as internal control (house
keeping genes). Leucine-rich repeat kinase 2 (LRRK2), Leucine-
rich repeat kinase 1 (LRRK1), cluster of differentiation -3 (CD3),
-4 (CD4), -8a (CD8a), -14 (CD14), -16 (CD16) and -19 (CD19). In
all following experiments values of other genes were expressed as
percentage of these three housekeeping genes.
(TIF)
Figure S2 Validation of data obtained with the LRRK2
antibody ab60937 from Abcam using two additional
LRRK2 antibodies. Experiments performed with AT106 from
Alexis Biochemicals (panel A) or with MJFF3-c69-6 from
Epitomics Inc. (panel B), confirmed the higher LRRK2 protein
content in CD14
+CD16
+ monocytes as compare to CD14
+
CD16
2 cells. Western blots were performed the same day from
the same material. Monocytes sub-populations were purified
from hPBMC using immunomagnetic beads and all fractions
including starting material (hPBMC) were loaded on the gel.
CD14
+ and CD14
- respectively refer to monocytes and other cell
types that are not expressing CD14. LRRK2 immunoreactive
band is highlighted by the arrow. LRRK2 protein quantification
was performed using the LI-COR OdysseyH and results are
expressed in function of actin. Note that AT106 is also giving an
additional band above LRRK2. As this band was not found
using ab60937 or MJFF3-c69-6 antibodies, we did not consider it
for LRRK2 quantification.
(TIF)
Figure S3 FACS assessment of CD14
+ and CD14
+CD16
+
enrichment from hPBMCs. FACS sorting of hPBMC sub-
populations showing consecutives enrichment in CD14
+ and
CD14
+/CD16
+ monocytes. (1) At the beginning total PBMCs
contained vast majority of CD14
2/low cells corresponding to
T-lymphocytes (bottom left quadrant) and NK cells (top left
quadrant). (2) CD14
+ enrichment using negative selection
discarded most of T and NK cells, leaving a CD14
+CD16
+ and
CD14
+/CD16
2 mixed population. (3) This mixed population
could be further worked on to purify CD14
+CD16
2 sub-
population to homogeneity or to enrich CD14
+CD16
+ cells using
CD16
+ positive selection.
(TIF)
Figure S4 Time-course expression of LRRK2 by hPBMC
stimulated by IFN-c. At different times with or without IFN-c
(30 IU/mL) treatment cells were collected and LRRK2 mRNA
expression quantified by qPCR. Increased expression was
compared to time matching control without IFN-c.( *p ,0.05,
** p,0.01, *** p,0.005, Student t-Test, n=3 for each point).
(TIF)
Figure S5 Effect of various cytokines on LRRK2 expres-
sion by hPBMCs. (A) and (B) Effect of various cytokines on
LRRK2 and LRRK1 mRNA expression by hPBMC was
monitored after 24 h of culture. LRRK2 protein content was also
assessed (C). IFN-c (0.1, 10 and 100 IU/mL); LPS (50 ng/mL),
TNF-a (10 ng/mL), IGF-1 (25 ng/mL), IL-1b (25 ng/mL), IFN-b
(100 IU/mL), IL-2(10 ng/mL),IL-6(10 ng/mL), IL-1510 ng/mL
and H2O2 (30 mM) were added at plating time. PBMC refers to
freshly purified PBMC (starting material) and control refers to
untreated hPBMC after one day in vitro. Western blot are
representative of at least two independent experiments (except for
IL-2, Cf. Table-I). mRNA values are expressed as percent of house
keeping genes (%HKG). Statistical difference in normalized
LRRK2 or LRRK1 mRNA amounts were calculated against
values obtained on freshly isolated cells (* p,0.05; ** p,0.01,
*** p,0.005, One Way Anova, with Bonferroni post-test; n=3 for
each point).
(TIF)
Figure S6 Assessment of monocytes activation by IFN-c
treatment of hPBMCs. Twenty four hours after in vitro
treatment with IFN-c (30 IU/mL), total PBMC (top panel) or
purified monocytes (bottom panel) were harvested and analysed by
FACS for various activation markers. Graph represents the
number of cells (Events count) in function of staining intensity
(Fluorescence Intensity). The shift towards high level of I-CAM
(CD54), a molecule involved in cell adhesion, is characteristic of
monocyte activation in response to IFN-c. Note the similarity
between the shift in PBMC and in purified monocytes populations.
As lymphocytes also express CD54 another cell adhesion molecule
L-selectin (CD62L) was measured. The absence of CD62L shift in
response to IFN-c and the low expression level of CD62L by
monocytes confirmed that CD54 increase was due to monocytes
activation. Finally, we studied the expression of a co-stimulatory
signal ligand for T cells (CD80) expressed on B-cells and
monocytes once activated. In PBMC as on purified monocytes
we detected a slight shift in CD80 expression. CD80 expression
will further increase with former maturation of monocytes.
(TIF)
Figure S7 Serum free conditions induced LRRK2 ex-
pression by hPBMCs. PBMCs were plated in presence or
absence of 10% foetal calf serum. Ninety minutes later medium
was complemented with 10% FCS. Cultures were thereafter
treated or not with IFN-c (30 IU/mL) and cells collected 24 h
later. LRRK2 protein levels were determined by western blot.
Transient plating in serum free conditions induced LRRK2
expression but did not blunt IFN-c response. Representative
western blot of three independent experiments is shown.
(TIF)
Figure S8 FACS analysis of monocytes maturation
towards DC and macrophages. Purified monocytes
CD14
+CD16
+/2 populations were matured for 7 days in vitro
with IL-4/GM-CSF towards dendritic cells (DC) or with LPS
towards macrophages (MF) phenotypes. DC and MF are very
heterogeneous in term of cell surface markers expression. As
expected after 7 days of in vitro maturation, LPS treated monocytes
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High, CD16
+,
CD80
+, CD83
+, CD103
+ and CD206
High meanwhile IL-4/GM-
CSF treated monocytes are DC like (black line) with a CD14
Low,
CD16
Low, CD80
High, CD83
+, CD103
+ and CD206
+ pattern. The
initial pattern obtained with purified monocytes one day after
plating (red line) is included to highlight the switch in maturation
markers expression.
(TIF)
Figure S9 FACS analysis of monocytes maturation
towards macrophages. To further document the induction
of macrophage phenotype by LPS, additional macrophage
markers, namely CD40, CD68 and CD71 were tested. After 7
days in vitro with LPS, monocytes CD14
+CD16
+/2 populations
matured towards macrophages (MF) phenotypes with elevated
expression of CD14
High, CD40
+, CD68
+ and CD71
+ (orange
line). The initial pattern obtained with purified monocytes one day
after plating (red line) is included to highlight the switch in
maturation markers expression.
(TIF)
Figure S10 Effect of LRRK2 inhibitors on IFN-c-induced
cell surface markers by monocytes. After background
determination using non-labeled cells and cells labeled with
control isotypes, the threshold was set-up on IFN-c (B) versus
untreated (A) cells. With an average fluorescence value of 1.10
+2,
IFN-c treatment (light blue line) induced a very strong shift in
CD14
+ (C) and CD16
+ (D) expression as compare to untreated
monocytes (red line). Due to endogenous high expression, MHC-II
shift in response to IFN-c was less obvious but still significant (E).
Effects of 10 mM (dark line) and 0.1 mM (light grey) of IN-1 on
CD14, CD16 and MHC-II expression were presented. At 10 mM
IN-1 blocked IFN-c -induced CD14, CD16 and MHC-II
expression (p,0.005, p,0.005 and p,0.05, respectively. One-
way-ANOVA, Bonferroni post-hoc test, n=3 for each).
(TIF)
Figure S11 Analysis of transcriptome data from Inger-
soll et al., to assess expression of LRRK2 mRNA by
CD14
++CD16
2 and CD14
+CD16
+ monocytes subpopula-
tions. Differential gene expression was performed between
CD14
++CD16
2 and CD14
+CD16
+ purified monocytes (Ingersoll
et al., Comparison of gene expression profile between human and
mouse monocyte subsets, Blood (2010) 115:e10-e19). Re-analysis
of the expression data published in Gene Expression Omnibus
(GEO) databank, accession GSE 18565 (human), revealed that
LRRK2 and LRRK1 mRNA are not differentially expressed
between CD14
++CD16
2 and CD14
+CD16
+ monocytes.
(TIF)
Figure S12 LRRK2 but not LRRK1 promoter has
extended 59 end. LRRK1 and -2 display similar intron-exon
organization. However, LRRK1 is considerably shorter at the 59
end.
(TIF)
Figure S13 LRRK2 promoter has multiple 59 potential
GAS/ISRE sites. IFN-c inducible transcription factor ICSBP/
IRF8 binds a set of DNA binding sites. Among these, ISRE and
ICS contain the IRF recognition sequence (IRS), AANNGAAA,t o
which the DBD of the IRF family binds (see J. Interferon Cytokine
Res. 22:145–152 (2002) for a review). Transcriptional activity
further depends on the context and presence of additional
proteins. Analysis of the LRRK2 proximal promoter reveals that
five IRS such AANNGAAA (red underlined) consensus sequences
are present.
(TIF)
Figure S14 LRRK2 but not LRRK1 promoter has
multiple 59 potential GAS/ISRE sites. The 2 kbp promoters
show no significant sequence similarity (highlighted in green)
suggesting divergent transcriptional regulation. In contrast to
LRRK2 promoter, no AANNGAAA sequence is found in the
proximal LRRK1 region. While we have not established that these
represent bona fide IRS elements it appears likely that at least a
subset of these is involved in the observed IFN-c -inducible
LRRK2 expression, in contrast to LRRK1.
(TIF)
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